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AbstrAct
Contemporary therapies for patients with glioblastomas remain marginally efficient, and 
recurrence following surgery, radiation therapy and adjuvant chemotherapy is practically 
universal. The major obstacles to the successful use of chemotherapy for CNS tumors are 
the drug delivery to the tumor site and the infusion of chemotherapeutic agents directly 
into the arterial supply of a tumor. The latter could provide a pharmacokinetic advantage 
by enhancing drug delivery to the tumor. Sixteen patients with recurrent unilateral 
glioblastomas treated with intra-arterial BCNU were evaluated retrospectively. During the 
infusion, eleven patients referred pain in the ipsilateral eye, five patients were nauseated, 
three reported headache, one patient presented mental confusion, while two presented 
focal signs. There were two deaths during the course of therapy. Four patients achieved 
temporary clinical improvement, seven showed disease stability, and three presented 
clinical deterioration. The median total survival time was 87.9 weeks. Unilateral vision loss 
and focal signs were observed as delayed complications of this treatment. This study has 
confirmed previous reports indicating that arterial chemotherapy is clearly not curative, 
and presents serious toxicity. Only through a randomized prospective study performed 
in a large series of patients can the questions concerning survival period increment be 
answered properly.
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tratamento do glioblastoma recorrente com bcNU [1, 3-bis (2-chloroethyl)-1-nitrosourea] 
intra arterial
resUmo
Os tratamentos atuais para pacientes com glioblastoma permanecem pouco eficientes 
e a recorrência, acompanhando cirurgia, radioterapia e quimioterapia, é a regra geral. 
O maior obstáculo para o sucesso da quimioterapia para os tumores do SNC é a 
disponibilização da droga no sitio do tumor sendo que a infusão do agente quimioterápico 
diretamente na trama arterial da lesão pode proporcionar vantagens por maior liberação 
da substância diretamente no tumor. Estudamos retrospectivamente dezesseis pacientes 
com glioblastomas recorrentes, unilaterais, que foram tratados com BCNU intra-arterial; 
durante a infusão, onze pacientes sentiram dor no olho ipsilateral, cinco ficaram nauseados, 
três queixaram-se de cefaléia, um apresentou confusão mental e dois apresentaram sinais 
focais. Ocorreram duas mortes durante a terapia. Quatro pacientes apresentaram melhora 
clinica temporária, sete apresentaram estabilização e três apresentaram deterioração. A 
média de sobrevida total foi de 87,9 semanas. Perda da visão unilateral e sinais focais 
foram complicações tardias. Este estudo confirmou trabalhos anteriores indicando que Correspondence
Eberval Gadelha Figueiredo
Rua Oscar Freire 1399 / Apto 171
05409-010 São Paulo SP - Brazil
E-mail: ebgadelha@yahoo.com
Received 27 August 2009
Received in final form 17 April 2010
Accepted 27 April 2010
Division of Neurosurgery, University of São Paulo, School of Medicine, São Paulo SP, Brazil: 1Supervisor, Division of 
Neurological Surgery, University of São Paulo Medical School, São Paulo SP, Brazil; 2Fellow Physician, Division of Functional 
Neurological Surgery, University of São Paulo Medical School, São Paulo SP, Brazil. Chief of Division of Neurological Surgery, 
Federal University of Uberlândia Medical School, Uberlândia MG, Brazil; 3Chairman, Division of Neurological Surgery University 
of São Paulo Medical School, São Paulo SP, Brazil.
Arq Neuropsiquiatr 2010;68(5)
 779
Glioblastoma treatment with BNCU
Figueiredo et al.
Contemporary therapies for patients with malignant 
gliomas remain only marginally efficient, and the recur-
rence rate following surgery, radiation therapy and adju-
vant chemotherapy is practically universal. There are sev-
eral challenges related to the treatment of central ner-
vous system (CNS) tumors with chemotherapy. Among 
these challenges, the heterogeneity of malignant prima-
ry brain tumors, presenting with a variety of histological 
subtypes and similar tumors may be responsible for the 
different tumor behavior regarding treatment. Addition-
ally, the number of chemotherapeutic agents available to 
treat a variety of CNS tumors is limited1, while drug re-
sistance involving P-glycoprotein2 and the ability of tu-
mor cells to repair DNA damage induced by cytotoxic 
agent or the use of alternative pathways of metabolism3 
also have to be considered. 
Failure to eradicate local tumor growth is a major fac-
tor contributing to poor outcome, as indicated by the de-
velopment of 90% of glioblastoma (GBM) recurrences at, 
or adjacent to, the original tumor4. A major obstacle for 
the successful use of chemotherapy for CNS tumors drug 
delivery to the tumor site. CNS tumor response to che-
motherapy is limited by inadequate intracellular concen-
trations of the drug, inadequate drug exposure time and 
characteristics of drug delivery across the blood brain 
barrier (BBB). There is a challenge on the ability for drug 
delivery across the BBB, a physical and physiologic barri-
er that regulates the entry of molecules to the brain. The 
BBB is highly effective for protecting the CNS from vari-
ous toxins, but it is also effective at excluding therapeutic 
agents such as chemotherapies and antibiotics5. Iatrogen-
ic disruption of the BBB prior to administering systemic 
chemotherapy has had greater success6. 
Nitrosoureas, which include BCNU (1,3-bis(2-
chloroethyl)-1-nitrosourea), are the primary single-agent 
therapy used for the treatment of gliomas7. Nitrosoureas 
are small, lipid-soluble, non-ionized alkylating agents8, 
which have been administered into the arteries (IA), with 
some success9. However, the positive responses have been 
modest, and the technique is associated with significant 
toxicity. Furthermore, its true activity for patients with re-
current or progressive malignant gliomas remains uncer-
tain. The literature reports single-agent response rates of 
40% to 50%, but this is seldom seen in the clinical prac-
tice. The real objective response rate of nitrosoureas re-
mains unknown, although many authors believe it to be 
less than 10% for glioblastoma9. So far, IA administration 
alone has not really shown improvement in the outcome 
for patients with brain cancer10,11, and no study has yet 
demonstrated a significant benefit of intra-arterial che-
motherapy over its intravenous counterpart12.. No large 
randomized trial has yet demonstrated that intracarotid 
administration of chemotherapy is more advantageous 
than its systemic administration13. The objective of this 
paper is to evaluate and describe the treatment of recur-
rent glioblastoma with intra-arterial BCNU.
METHOD
Sixteen patients with postoperative recurrent, uni-
lateral, supratentorial glioblastomas in the medial cere-
bral artery territory were referred for intra-arterial ca-
rotid infusion chemotherapy using Seldinger technique. 
All patients had been submitted to surgery (3 biopsy and 
13 craniotomy), and had previously received whole brain 
radiotherapy (RT) consisting of a median dose of 6,000 
rads (one patient received 5,000 rads) No patient had pre-
viously received chemotherapy. The corticosteroid dex-
amethasone was administered when clinically indicated, 
with the dose adjusted at weekly intervals; and diphe-
nylhydantoin and phenobarbital were used as anticon-
vulsant agents. Written informed consent was obtained 
from all patients.
Patients were eligible for this treatment if the following 
criteria were met: [1] the tumor was histologically con-
firmed as glioblastoma; [2] the tumor was recurrent; [3] 
radiotherapy had been administered; [4] white blood cell 
count was >4,000/mm3 and platelet count was >125,000/
mm3; [5] liver and renal functions were <2 times high-
er than normal values; [6] Karnofsky performance status 
at time of study entry was ≥70%. Active infections and 
pregnancy were considered as exclusion criteria for pa-
tient selection. A neurological examination with Karnof-
sky functional performance rating, complete blood count, 
and platelet count were performed during treatment. Pa-
tients were premedicated with Inoval® (Droperidol and 
Fentalina) 2 ml IV during the drug infusion, as required.
BCNU was administered through a selective inter-
nal carotid artery catheter placed percutaneously, using 
the femoral approach and immediately prior to infusion. 
BCNU was dissolved in 1.0 ml of absolute ethanol/100 
mg BCNU, and given at 250 mg per square meter of body 
surface area. It was then made up to a volume of 150 cc 
a quimioterapia intra-arterial claramente não é curativa, séria toxicidade pode ocorrer e 
somente um estudo prospectivo e randomizado, realizado em uma serie maior de pacientes, 
poderá responder questões sobre o aumento do tempo de sobrevida de forma adequada.
Palavras-chave: gliomas malignos, quimioterapia, carmustina, artéria carótida, artéria 
oftálmica.
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with normal saline, and this solution was infused using an 
infusion pump, at 400 to 600 cc/hr. In all patients, these 
treatments were repeated every 6 weeks. Follow-up was 
carried-out on an outpatient basis, for 117 weeks in av-
erage. Complications related to the procedure were listed 
and neurological final outcome was retrieved from hospi-
tal records. Data are summarized in the Table.
RESULTS
Sixteen patients with recurrent unilateral glioblasto-
mas were treated with pulse dose of IA BCNU via trans-
femoral internal carotid catheterization. There were no 
complications related to the use of the catheter and the 
desired placement was achieved in all cases. During the 
infusion, eleven patients felt moderately severe pain in 
the ipsilateral eye, and five patients were nauseated for 3 
to 5 hours following the infusion. Three patients reported 
headache, one patient presented mental confusion, while 
two patients presented focal signs and three patients had 
amaurosis. There were two deaths related to the tumor 
during the course of therapy. Karnofsky rating improved 
in four patients, worsened in three patients, and remained 
unaltered in seven patients (stable disease). After three to 
seven cycles of chemotherapy, six patients showed a de-
crease in tumor size and in the surrounding edema, as as-
sessed by contrast enhanced CT scanning, in cases with 
partial response. Ten patients presented no changes and, 
in this group, three had not undergone CT scan. Four pa-
tients achieved a temporary period of clinical improve-
ment, seven patients had stable disease and three patients 
presented neurological deterioration. The median surviv-
al time from the onset of chemotherapy in the group of 16 
patients was over 66.6 weeks. The median survival time 
from the operation act was over 21.3 weeks. The median 
total survival time was over 87.9 weeks. Unilateral loss of 
vision was a delayed complication in three patients, while 
two patients developed focal signs and recognized leuko-
encephalopathy or tumor necrosis. Patients’ characteris-
tics are listed in the Table.
DISCUSSION­
Chemotherapy is currently being used as an adjunc-
tive treatment for malignant primary tumors, progres-
sive benign tumors, and recurrent or resistant tumors. 
The treatment of glioblastoma at recurrence remains pal-
liative with only small numbers of long-term responses. 
In the present series, cases of combined prior radiother-
apy, surgery and consecutive intra-arterial BCNU were 
assessed for patients with unilateral supratentorial glio-
blastoma. A modest improvement in the median survival 
with the addition of single-agent or combination chemo-
therapy to radiotherapy has been demonstrated in several 
trials14. An additional study that reviewed data from two 
Brain Tumor Study Group protocols (including patients 
with glioblastoma multiforme and other types of anaplas-
tic gliomas) demonstrated an increased number of long-
term survivors in the group of patients who received ad-
juvant chemotherapy with BCNU compared with radia-
tion alone, regardless of prognostic factors15,16. A meta-
analysis of 16 randomized clinical trials, which included 
more than 3000 patients treated between 1975 and 1989, 
demonstrate a survival benefit for those patients with ma-
lignant glioma treated with radiation and adjuvant che-
motherapy compared with those treated with radiation 
therapy alone17. Some studies indicate a modest benefit 
of the single agent BCNU when added to RT17,18. 
Malignant astrocytomas can be treated with IA BCNU 
followed by radiation therapy with a therapeutic efficacy 
that appears to be equal to or better than that of radiation 
therapy followed by IV BCNU19. Infusion of chemother-
apeutic agents directly into the arterial supply of a tumor 
Table. Patient characteristics.
characteristics Intra-arterial (n=16)
Sex (M/F) 10/6
Age 
   Median 55
   Range 48-67
KPS
   Median 80
   Range 70-100
Tumor location
   Frontal 4
   Frontotemporal 3
   Frontoparietal 3
   Parietal 3
   Temporoparietal 2
   Parieto-occipital 1
Pretreatment
   Biopsy 3
   Craniotomy 13
Repeat surgery 1
Radiotherapy
   6,000 rd 15
   5,000 rd 1
Number of cycles
   Median 10
   Range 6-12
Survival after surgery 21.3 weeks
Survival after chemotherapy 66.6 weeks
Total survival (M) 97.9 weeks 
KPS: Karnofsky performance score.
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can provide a pharmacokinetic advantage by enhancing 
drug delivery to the tumor without increasing systemic 
drug exposure20,21. Intra-arterial (IA) administration of a 
drug is designed to increase the drug-concentration de-
livered to a vascular territory by eliminating the first pas-
sage metabolism. However, for drugs that have rapid tran-
sit trough the CNS, there may be limited dwell time, re-
sulting in limited efficacy. In a study involving 12 adults 
patients with recurrent glioblastoma, intra-arterial BCNU 
infusion resulted in a median survival time of 54 weeks 
following recurrence (92 weeks after diagnosis). Howev-
er, no major improvement in survival time was demon-
strated in a group of 43 patients treated adjuvantly after 
receiving irradiation. It was hypothesized that the group 
receiving adjuvant intra-arterial BCNU had radiation-re-
lated changes that limited drug penetration into tissue, al-
though the effects of radiation on drug delivery across the 
BBB have been controversial22. A study by Levin and col-
leagues using radiolabeled BCNU demonstrated a four-
fold increase in BCNU concentration in the brain fol-
lowing intracarotid administration compared with intra-
venous administration23. A study using continuous-infu-
sion of cisplatin plus BCNU before RT demonstrated no 
improvement in survival compared with RT and BCNU 
alone24. On the other hand, the simultaneous administra-
tion of cisplatin and BCNU, together with RT, resulted in 
more toxicity and provided no significant improvement 
in survival25. The comparison of intra-arterial ACNU 
and carboplatin versus intravenous cisplatin and BCNU 
in newly diagnosed patients with glioblastoma provid-
ed no conclusive evidence of benefit for either method26. 
The mean survival duration in the present study was 87.9 
weeks after diagnosis; 21.3 weeks after surgery; and 66.6 
weeks after chemotherapy.
In a study combining intra-arterial (IA) and system-
ic chemotherapy in patients with grade II to IV gliomas, 
response rates up to 54% were demonstrated, but 31% of 
patients developed neurotoxicity, while 12% developed 
serious permanent local toxicity27. In the present study, a 
delayed complication of unilateral loss of vision was ob-
served in three patients, while focal signs and recognized 
leukoencephalopathy or tumor necrosis were observed 
in two cases. Tissue regions that receive high concentra-
tions of the drug are at risk for toxicity, whereas low drug 
concentrations in other tissue regions may be subthera-
peutic28. In addition to increasing drug levels in the tu-
mor, IA technique increases drug levels in the area of nor-
mal brain that is supplied by that artery, leading to great-
er neurotoxicity. For example, intracarotid administra-
tion of BCNU has been associated with ocular toxicity, 
stroke, and an encephalitic profile29. The ocular compli-
cations of intracarotid infusion of drugs for brain-tumor 
chemotherapy may be reduced by infusion of the chemo-
therapeutic agent into the carotid artery above the origin 
of the ophthalmic artery30. One difficulty with the intra-
arterial administration is that there may be no uniform 
drug distribution within the brain or the tumor after the 
intracarotideal infusion, due to poor mixing or stream-
ing of the drug solution within the artery31. Similarly, in 
patients undergoing resection for recurrent GBM, place-
ment of carmustine wafers only provided a modest ex-
tension of survival32. Implanted therapies with polymer-
based drug delivery, placed in the surgical cavity at the 
time of the tumor debulking, resulted in improved sur-
vival of roughly 2 months32,33. The ocular complications 
of intracarotid infusion of drugs for brain-tumor chemo-
therapy may be minimized by infusion of the chemother-
apeutic agent into the carotid artery above the origin of 
the ophthalmic artery30. Additionally, the frequency of vi-
sual loss could be decreased if the concentration of the 
ethanol diluent was lowered19.
There are controversial data questioning the increase 
in survival time with associated radiotherapy and chemo-
therapy, the optimal dosage of chemotherapy, the role of 
intra-arterial treatment, the real toxicity of drugs associa-
tion and the best place to infuse the drugs. The treatment 
of glioblastoma multiforme remains a difficult problem 
for neurosurgeons. The present study has corroborated 
the observation that intra-arterial chemotherapy is clear-
ly not curative, with serious toxicity. Therefore, only ran-
domized prospective studies performed on a large series 
of patients may answer these problems properly.
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